Alpelisib (BYL719)

For research use only.

Catalog No.S2814

119 publications

Alpelisib (BYL719) Chemical Structure

CAS No. 1217486-61-7

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 592 In stock
USD 370 In stock
USD 570 In stock
USD 870 In stock
USD 1270 In stock
USD 1670 In stock
USD 2670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Alpelisib (BYL719) has been cited by 119 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.
Targets
PI3Kα [1]
(Cell-free assay)
5 nM
In vitro

BYL719 inhibits the proliferation of breast cancer cell lines harboring PIK3CA mutations, correlating with inhibition of various downstream signaling components of the PI3K/Akt pathway. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4SyfFAvOS1zMECg{txO M1TJcFczKGh? NUHDVG0yUUN3ME2xMlExKM7:TR?= M4foWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
SNU-1076 NXfHbYtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K0VlAvOS1zMECg{txO MlfwO|IhcA>? NF\CcJhKSzVyPU[uPFIh|ryP NV\kW4hORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVA2PDlpPkK1OVUxPTR7PD;hQi=>
SNU-1066 M37CTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XvbVAvOS1zMECg{txO NGSyTnY4OiCq MlLBTWM2OD1zLkGzJO69VQ>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3MEW0PUc,OjV3NUC1OFk9N2F-
FaDu MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2wMlEuOTByIN88US=> MVy3NkBp M3vPPGlEPTB;MUmuOlYh|ryP MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3MEW0PUc,OjV3NUC1OFk9N2F-
SNU1041 M{Xh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKwMlEuOTByIN88US=> M{DpZVczKGh? NHvBVIVKSzVyPUKwMlY2KM7:TR?= NHj4Z5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SCC25 NFP5d5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLtNE4yNTFyMDFOwG0> NHm1SJM4OiCq M4OxbWlEPTB;NEmuN|Ah|ryP M4j4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
BON-1 M12xfGZ2dmO2aX;uJGF{e2G7 M{D5UFEwOTBizszN MkfROEBp M3XnR4lvcGmkaYTzJHBKO0tiKFHLWEBU\XJ|MEipJIFv\CCvVF;SR|EwOiCjY4Tpeol1cWW| MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
QGP-1 MVHGeY5kfGmxbjDBd5NigQ>? NHnISYsyNzFyIN88US=> MVO0JIg> MV3pcohq[mm2czDQTVNMKCiDS2SgV4VzOzB6KTDhcoQhdVSRUlOxM|Ih[WO2aY\peIlmew>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{NkK5Nkc,OjVyMk[yPVI9N2F-
MG-63 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTRN5NKSzVyPU[g{txO97zOIFnDPVA:OjRizszN NGDa[HM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NVc6OCd-MkS5OlE4QTB:L3G+
HOS Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITBOoNKSzVyPUG1JO69Ve,:jDDJR|kxRTR{IN88US=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4MUe5NEc,OjR7NkG3PVA9N2F-
MOS-J NHT1UnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPE[m1KSzVyPUGwJO69Ve,:jDDJR|kxRTN4IN88US=> NYe2eIZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
POS-1 M3z0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe1cXRCUUN3ME24JO69Ve,:jDDJR|kxRTN4IN88US=> NVG0U5pCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
92.1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Gd4RvPTByLUKwNFAhdk1? MV21JIQ> M{H5OYlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO M2\kNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
Mel270 NFHRXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DOOVUxOC1{MECwJI5O NGXFXFY2KGR? NIrDNmRqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? M4G4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
Omm1.3 MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInoRoQ2ODBvMkCwNEBvVQ>? MW[1JIQ> M{fC[IlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO NIixfG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|U1OCd-MkS1OlM2PDB:L3G+
Omm1 NIn3R5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[1NFAuOjByMDDuUS=> NVjIWINDPSCm NX3oW3o5cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1? M3nUfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
C918 NHOxbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe1NFAuOjByMDDuUS=> MYC1JIQ> MkfHbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> M3jrZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N|U1ODxxYU6=
Mel290 M2Xndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLseXA2ODBvMkCwNEBvVQ>? M33NTlUh\A>? MYDpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4M{W0NEc,OjR3NkO1OFA9N2F-
OPM2 NHLMWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXpNE42NTJwNTFOwG0> MYm0PEBp NELLSnBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
OPM1 NInGS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrxNFYxNjVvMj61JO69VQ>? M3TRZVQ5KGh? NWLhUYRFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
U266 NFm2fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33yelAvPS1{LkWg{txO MVi0PEBp NWjIS5Q6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NInDbVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
MM1R MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHlNE42NTJwNTFOwG0> M2PWWlQ5KGh? MlH4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
MM1S NU\Pfo1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrlPHhLOC53LUKuOUDPxE1? MVq0PEBp NV7DfYRscW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
H929 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMlUuOi53IN88US=> Ml7POFghcA>? Mn\pbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVS4U2pzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFUyOjFpPkK0OFA2OTJzPD;hQi=>
RPMI M2SxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmwMlUuOi53IN88US=> M2C1TFQ5KGh? Mn[0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGrrR4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
SKBR3 NVuybJJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSxNHYxOzNizszN NUK5R5ltPSCm M3P1XYlvcGmkaYTzJFM297zHIHPlcIwh\3Kxd4To NUnHdGVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
MDA453 NEGxPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjDZ|R7OzNizszN NVrzV2RXPSCm MYfpcohq[mm2czCzPQ+9jSClZXzsJIdzd3e2aB?= NV;ITppIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
EFM192A NF7HUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHLN|Mh|ryP NFPjTG02KGR? MoH5bY5pcWKrdIOgNlfwxIViY3XscEBoem:5dHi= NWPQV2RJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
AU565 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYezN{DPxE1? MknKOUBl NF3lXm5qdmirYnn0d{AzPu,:hTDj[YxtKGe{b4f0bC=> MoT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
MDA361 NGrCV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnwN|Mh|ryP M1PYe|Uh\A>? NWPNNXN6cW6qaXLpeJMhPDUxvJWgZ4VtdCCpcn;3eIg> M1\0U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
BT474 M2q1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n0TFM{KM7:TR?= M{T3TlUh\A>? NWLtWXozcW6qaXLpeJMhOTcxvJWgZ4VtdCCpcn;3eIg> NWq4VlJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
HCC202 M3nGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOzN{DPxE1? NF3XW|g2KGR? NIH4[3BqdmirYnn0d{AzOO,:hTDj[YxtKGe{b4f0bC=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
KPL4 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfoN|Mh|ryP MWe1JIQ> NH;XbmlqdmirYnn0d{A2QO,:hTDj[YxtKGe{b4f0bC=> NFvMPGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
NCL-N87 NH3xfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;CUVE{OyEQvF2= M17LZ|Uh\A>? NXX3cGhXcW6qaXLpeJMhOzIxvJWgZ4VtdCCpcn;3eIg> MlvuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
UACC812 M1[5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSyN|Mh|ryP M2fnR|Uh\A>? NEXoR|BqdmirYnn0d{AzP+,:hTDj[YxtKGe{b4f0bC=> M1vRU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
HCC2218 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTNN|Mh|ryP NGDmNZA2KGR? NF7PdnZqdmirYnn0d{AyPe,:hTDj[YxtKGe{b4f0bC=> M4DJWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
HCC1569 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGyZlM{OyEQvF2= MmTVOUBl MnnnbY5pcWKrdIOgOg+9jSClZXzsJIdzd3e2aB?= NV35Oop5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
OE19 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKzN{DPxE1? NUjDOZZZPSCm NVnr[GIzcW6qaXLpeJMhOjQxvJWgZ4VtdCCpcn;3eIg> NVjCPW1ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
OE33 M2j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDa[ms{OyEQvF2= MWm1JIQ> NVKzfJh[cW6qaXLpeJMhOjQxvJWgZ4VtdCCpcn;3eIg> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
JIMT1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:1ZYtkOzNizszN M1\OeVUh\A>? NFq3R|RqdmirYnn0d{A697zHIHPlcIwh\3Kxd4To NFTldoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
HCC1954 NFf5ZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPwN|Mh|ryP MXm1JIQ> M2TTN4lvcGmkaYTzJFI697zHIHPlcIwh\3Kxd4To NILnU3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
NUGC4 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX6bYRuOzNizszN NX3Ee45MPSCm M2Dqd4lvcGmkaYTzJFE197zHIHPlcIwh\3Kxd4To NGK3T5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
ZR-75-30 M1PBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTGN|Mh|ryP MWS1JIQ> MlrYbY5pcWKrdIOgMVE297zHIHPlcIwh\3Kxd4To NYPzco9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
Rat1 MXnQNVEx[WyyaHGgbY5pcWKrdHnvckBie3OjeR?= M1;KRWlEPTBiPTCwMlA4PCEQvF2= M2fFflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[0NVg6Lz5{NkG2OFE5QTxxYU6=
Rat1 NYjBW|FuWEl|S3HsdIhiKGmwaHnibZRqd25iYYPzZZk> NIXveINKSzVyIE2gNE4xPzRizszN NXfFS4tQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFY2ODRpPkK2NlA3PTB2PD;hQi=>
Rat1 NIXQVllROTFyYXzwbIEhcW6qaXLpeIlwdiCjc4PhfS=> MoD4TWM2OCB;IECuNFc1KM7:TR?= Moe1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mk[wN|QoRjJ|N{K2NFM1RC:jPh?=
Rat1 NVzzd5lrWDFzMHTlcJRiKGmwaHnibZRqd25iYYPzZZk> NFHQZmpKSzVyIE2gNU4zKM7:TR?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4NEG4PUc,OjZzNkSxPFk9N2F-
Rat1 NH\2ZYtRUTONZ3HtcYEhcW6qaXLpeIlwdiCjc4PhfS=> NEfGRlZKSzVyIE2gNU4zKM7:TR?= NX\6fnIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFY2ODRpPkK2NlA3PTB2PD;hQi=>
Rat1 NXyyXnZRWDFzMHTlcJRiKGmwaHnibZRqd25iYYPzZZk> MVTJR|UxKD1iMT6yJO69VQ>? NGrreWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyOlA{PCd-MkO3NlYxOzR:L3G+
Rat1 MlO1VFEyOGKndHGgbY5pcWKrdHnvckBie3OjeR?= Ml:0TWM2OCB;IEKuNkDPxE1? NY\NZmhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlQyQDlpPkK2NVY1OTh7PD;hQi=>
Rat1 MYjQTVNM[mW2YTDpcohq[mm2aX;uJIF{e2G7 M1nYZ2lEPTBiPTCyMlIh|ryP MoD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[1NFQoRjJ4MkC2OVA1RC:jPh?=
Rat1 NFzITnpROTFyYXzwbIEhcW6qaXLpeIlwdiCjc4PhfS=> MoniTWM2OCB;IEKuNkDPxE1? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{NkCzOEc,OjN5Mk[wN|Q9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT(S473) / p-AKT(T308); 

PubMed: 25544637     


PIK3CA hot-spot mutant cell lines were treated with 1 µM BYL719 for the indicated period of time. Lysates were immunoblotted to detect the indicated proteins.

p100β / p110α / p85 / p-ERBB3(Y1289); 

PubMed: 25544637     


BT474 cells were treated with 1 µM BYL719 alone for different durations of time and lysates were immunoprecipitated with ERBB3 antibody. Precipitates were analyzed by western blot with the indicated antibodies.

p-HER2 / IGF-1R; 

PubMed: 25544637     


Cells were treated with 1 μM BYL719 for 24 hr and lysates were immunoblotted to detect the indicated proteins.

pS6 (Ser235-236); 

PubMed: 27048245     


Immunoblots of lysates from parental and resistant cells treated for 24 hours as indicated.

PIM1 / PIM2 / PIM3 / p-PRAS40 / p-RPS6 / p-BAD; 

PubMed: 27604488     


T47D cells cultured to resistance in the presence of BYL719. Both parental (T47D) and resistant (T47DR) cells were treated with BYL719 at 1μM, and cell lysates were prepared at 0, 4, 24 hours for immunoblotting for the indicated proteins.

25544637 27048245 27604488
Growth inhibition assay
Cell viability; 

PubMed: 27602501     


The effect of BYL719 on cellular viability was evaluated in HCT116 (A) and SW480 (B) CRC cells. Briefly, cells were grown, treated with increasing concentrations of BYL719 (5, 10 and 20 μM) and cellular viability determined by MTS assay 72h after treatments. Controls included cells that remained untreated (media ctrl) and vehicle-treated controls (DMSO). Data represent means ± SEM of at least triplicate experiments normalized to controls. All conditions were compared with DMSO. Ctrl, control; DMSO, dimethyl sulfoxide. **, p< 0.01; ***, p< 0.001; ****, p< 0.0001.

27602501
Immunofluorescence
LC3; 

PubMed: 26637440     


SKBR3 GFP-LC3 cells were cultured for 5 days with DMSO, 500 nM BKM120 or 500 nM BYL719. Cells were treated with DMSO or 1 μM Lapatinib for the final 18 h. GFP-LC3 localization was captured by fluorescent microscopy.

26637440
In vivo BYL719(>270 mg/d) shows statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft models in rodents. BYL719 has a low clearance, a half-life of 8.5 h and its exposure increases dose proportionally between 30mg/d and 450mg/d, displaying a low inter-individual variability in Cmax and AUC in human. BYL719(270mg/d) shows first signs of clinical efficacy include 1 confirmed partial response in a patient with ER+ breast cancer, and significant PET responses (PMR) and/or tumor shrinkage are achieved in 8 out of 17 evaluated patients. [1]

Protocol

Solubility (25°C)

In vitro DMSO 88 mg/mL (199.33 mM)
Ethanol 2 mg/mL (4.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
4.4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 441.47
Formula

C19H22F3N5O2S

CAS No. 1217486-61-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04589650 Recruiting Drug: Alpelisib|Drug: Placebo PIK3CA-related Overgrowth Spectrum (PROS) Novartis Pharmaceuticals|Novartis April 19 2021 Phase 2
NCT04762979 Recruiting Drug: Alpelisib|Drug: Fulvestrant|Drug: Aromatase inhibitor Hormone Receptor Positive Breast Carcinoma|HER2-negative Breast Cancer|PIK3CA Mutant Metastatic Breast Cancer Amanda Parkes|Novartis|University of Wisconsin Madison|Big Ten Cancer Research Consortium February 12 2021 Phase 2
NCT04544189 Recruiting Drug: Alpelisib|Drug: Fulvestrant|Drug: Placebo Breast Neoplasms Novartis Pharmaceuticals|Novartis January 20 2021 Phase 2
NCT04524000 Recruiting Drug: Alpelisib|Drug: Fulvestrant Advanced Breast Cancer Novartis Pharmaceuticals|Novartis November 20 2020 Phase 2
NCT04300790 Recruiting Drug: Alpelisib|Drug: Metformin|Drug: Fulvestrant Breast Cancer MedSIR|Novartis October 23 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Alpelisib (BYL719) | Alpelisib (BYL719) supplier | purchase Alpelisib (BYL719) | Alpelisib (BYL719) cost | Alpelisib (BYL719) manufacturer | order Alpelisib (BYL719) | Alpelisib (BYL719) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID